Stay updated on Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial
Sign up to get notified when there's something new on the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page.

Latest updates to the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page
- Check3 days agoChange DetectedThe footer's ClinicalTrials.gov revision indicator was updated from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check11 days agoChange DetectedA banner announces NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.SummaryDifference0.8%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check25 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check45 days agoChange DetectedA newer revision, v3.7.0, was added to the record history, replacing the previous v3.6.6 entry and signaling an update to the study record.SummaryDifference0.1%

- Check66 days agoChange DetectedThe study record history now includes a new revision entry v3.6.6, and the previous revision v3.6.5 has been removed from the visible history.SummaryDifference0.1%

Stay in the know with updates to Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page.